Lessons From the ARCHER Trial - Report - MDSpire

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

  • By

  • Margaret Chang, MD

  • July 15, 2026

  • 2 min

Share

Clinical Report: Lessons From the ARCHER Trial

Overview

The ARCHER trial evaluated the efficacy of vonaprument in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

Background

Geographic atrophy is a late stage of non-neovascular AMD, characterized by progressive vision loss. Understanding risk factors for vision decline is crucial for developing effective treatments.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Vonaprument targets C1q, a key trigger in the complement cascade linked to GA.
  • Patients with baseline vision between 20/40 and 20/100 were at the highest risk for 15-letter vision loss.
  • Subfoveal lesions increased the risk of significant vision loss compared to nonsubfoveal lesions.
  • ARCHER trial results suggest that ≥15-letter loss is a meaningful endpoint in GA treatment.

Clinical Implications

The ongoing phase 3 ARCHER II study may provide further insights into the efficacy of vonaprument in preventing vision decline.

Conclusion

The ARCHER trial has highlighted risk factors for vision loss in GA.

Related Resources & Content

  1. Retinal Physician, 2025 -- Archer Study Analysis
  2. Retinal Physician, 2024 -- New ARCHER ANX007 in GA Treatment Findings Presented at ARVO
  3. Retinal Physician, 2025 -- Annexon Completes ARCHER Enrollment
  4. retinal physician — Video: Can Vonaprument Slow Vision Loss in GA?
  5. Age-Related Macular Degeneration Preferred Practice Pattern® - PubMed
  6. Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment - PMC
  7. Standardizing Measurement of Complete Retinal Pigment Epithelial and Outer Retinal Atrophy: Classification of Atrophy Meeting Report 8 - PubMed
  8. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed
  9. Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension - PubMed
  10. Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study - ScienceDirect
  11. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - ScienceDirect
  12. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials - ScienceDirect
  13. Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates - PMC
  14. JCI - Complement regulation in the eye: implications for age-related macular degeneration
  15. 10-K
  16. https://www.sec.gov/Archives/edgar/data/1528115/000119312526012918/d31215dex991.htm?utm_source=openai
  17. Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study - ASRS Multimedia Library
  18. Study Details | NCT06510816 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | ClinicalTrials.gov
  19. Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy | Annexon Inc.
  20. Annexon to Present Phase 2 ARCHER Baseline Characteristics

Original Source(s)

Lessons From the ARCHER Trial

  • by Margaret Chang, MD

  • July 15, 2026

Related Content

Expanding Optogenetics to Geographic Atrophy

Jordi Monés, MD, PhD, discusses the rationale for evaluating MCO-010 (sonpiretigene isteparvovec) in GA following encouraging findings in retinitis pigmentosa and Stargardt disease.

Optical coherence tomography acquisition efficiency: comparison of Heidelberg spectralis OCT2 module & Zeiss Cirrus HD-OCT model 6000

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.